These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 33979973)

  • 1. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
    Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
    Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].
    Zhang L; Li YL; Liu YM; Liu YB; Shang BJ; Cheng W; Dong XY; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):57-62. PubMed ID: 38178769
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficacy and prognostic analysis of orthopedic surgery in patients with newly diagnosed multiple myeloma].
    Zhang FJ; Zhou X; Liu SZ; Liu SJ; Liu Y; Zhuang JL
    Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):673-680. PubMed ID: 37263950
    [No Abstract]   [Full Text] [Related]  

  • 5. [Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma].
    Long XL; Wang XR; An N; Liu SY; Li Z; Li CH; Mu W; Wang D; Li CR
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):475-480. PubMed ID: 38964922
    [No Abstract]   [Full Text] [Related]  

  • 6. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study.
    Zhang F; Liu S; Zhou X; Wang W; Jia C; Wang Q; Liu Y; Zhuang J
    J Bone Oncol; 2024 Aug; 47():100615. PubMed ID: 39036812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
    Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
    PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
    Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
    Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
    Chao Y; Fan L; Gao XY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
    Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
    Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
    Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
    Bao L; Wang YT; Lu MQ; Chu B; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH; Liu X; Zhao X; Wang MZ; Chen Y; Hu WK
    Front Endocrinol (Lausanne); 2023; 14():1157969. PubMed ID: 37181039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
    Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
    Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
    Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and Clinical Significance of NAMPT in Bone Marrow of Patients with Multiple Myeloma].
    Wang YR; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1739-1744. PubMed ID: 38071054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.